Log In
Print
BCIQ
Print
Print this Print this
 

Rilotumumab (AMG 102)

  Manage Alerts
Collapse Summary General Information
Company Amgen Inc.
DescriptionHuman mAb against human hepatocyte growth factor/scatter factor (HGF/SF)
Molecular Target Hepatocyte growth factor/scatter factor (HGF/SF)
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase III
Standard IndicationGastric cancer
Indication DetailsTreat gastric cancer; Treat locally advanced or metastatic gastric or gastroesophageal cancer
Regulatory Designation

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today